Concepedia

Author

John R. Eckardt

The University of Texas Health Science Center at San Antonio

Also Known As

J ECKARDT, J Eckardt, J R Eckardt, J. Eckardt, J. R. Eckardt, J.R Eckardt, J.R. Eckardt, John Eckardt, John R Eckardt, John R. Eckardt

110

Publications

3.8K

Citations

33

H-Index

46

Concepts

All Affiliations

The University of Texas Health Science Center at San AntonioBrooke Army Medical CenterJoint Base San AntonioSt. John's UniversityArog Pharmaceuticals (United States)
JR

About

John R. Eckardt is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

29

1.3K

2

Health Sciences

11

12

626

3

Immunology

2

2

86

4

Natural Sciences

1

1

24

5

Molecular Biology

1

1

24

John R. Eckardt

×

55

Publications

3.5K

Citations

33

H-Index

YearCitations

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol,

Journal of Clinical Oncology

2007

380

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn,

Journal of Clinical Oncology

1996

351

Phase I and pharmacokinetic trial of weekly CPT-11.

Mace L. Rothenberg, John G. Kuhn, Howard A. Burris,

Journal of Clinical Oncology

1993

301

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

David Rinaldi, Howard A. Burris, F. Andrew Dorr,

Journal of Clinical Oncology

1995

152

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Zsolt Pápai,

Journal of Clinical Oncology

2006

146

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.

Howard A. Burris, Rebecca Irvin, John G. Kuhn,

Journal of Clinical Oncology

1993

135

Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies

Lisa A. Hammond, John R. Eckardt, Sharyn D. Baker,

Journal of Clinical Oncology

1999

132

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

Agop Y. Bedikian, Geoffrey R. Weiss, Sewa S. Legha,

Journal of Clinical Oncology

1995

95

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

John R. Eckardt, Dimitri L. Bentsion, Oleg Lipatov,

Journal of Clinical Oncology

2009

91

A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea

Gladys Rodriguez, John G. Kuhn, Geoffrey R. Weiss,

Blood

1998

82

Page 1